Rigosertib
As of the edition of 20 October 2026, Rigosertib is a small molecule: stopped in 2026; acts on CCND1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 36, 6 stopped early
- Disease areas
- Blood and lymph; Cancer; Digestive system; Immune system; Skin and connective tissue; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Rigosertib.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CCND1 | G1/S-specific cyclin-D1 | P24385 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 19 | 17 | 0 | 2 |
| Phase 2 | 13 | 10 | 0 | 3 |
| Phase 3 | 4 | 3 | 0 | 1 |
| All trials | 36 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Traws Pharma | Lead sponsor of trials | 2006 to now |
| SymBio Pharmaceuticals | Lead sponsor of trials | 2013 to now |